- BioTime Subsidiary offers 100 select recombinant proteins in its
BioReagents Portal -
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 10, 2013--
LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX),
announced today that it is now offering 100 selected ProSpec-Tany
TechnoGene (ProSpec) manufactured recombinant proteins related to stem
cell research in its recently launched LifeMap BioReagents™
portal (http://bioreagents.lifemapsc.com)
to researchers worldwide. ProSpec’s innovative recombinant proteins,
including growth factors, signaling molecules, differentiation factors,
hormones, cytokines and chemokines will complement the current BioTime
research product lines available via LifeMap BioReagents™,
including BioTime’s PureStem™ human progenitor cell lines, PureStem™
packages, clinical and research grade human embryonic stem cell lines
(hES), ESpan™ growth media for progenitor cell lines, and cell
differentiation media.
The addition of ProSpec products reflects LifeMap Sciences’
execution of its strategy to market a growing catalog of research
products to aid scientists in a variety of fields, including stem cell
research, developmental biology, mechanisms of various human diseases
and drug and therapeutic discovery.
LifeMap Sciences holds an exclusive, worldwide license to market GeneCards®
(www.genecards.org),
the human gene compendium, and MalaCards (www.malacards.org),
a database with nearly 17,000 human disease entries, from Yeda Research
and Development Company Ltd., the commercial arm of the Weizmann
Institute of Science. Additionally, it has recently launched version 1.1
of LifeMap Discovery™, a comprehensive embryonic development and
stem cell compendium, a database owned and developed by LifeMap
Sciences. According to Google Analytics, the sites have generated more
than 2,000,000 unique visitors with more than 13,000,000 page views in
the past 12 months. Links from LifeMap Discovery™ to BioTime and
ProSpec manufactured products in the LifeMap BioReagents™ portal
will enable researchers who access the database to become familiar with,
and purchase, products that relate directly to the types of cells, genes
or diseases that they are studying and can assist them in various
research projects.
“We are pleased to meet this significant milestone in our e-Commerce
strategy,” stated Yaron Guan-Golan, Head of Marketing at LifeMap
Sciences. “Our growing LifeMap Discovery™ user base will now be able to
identify high quality recombinant proteins that can be helpful for their
research and purchase them via LifeMap BioReagents™. This will
increase LifeMap BioReagents™ brand awareness and the quality of
our offering to the global biomedical research community.”
About LifeMap Sciences, Inc.
LifeMap Sciences’ (www.lifemapsc.com)
core technology and business is based on its integrated database suite,
the discovery platform for biomedical and stem cell research. This
platform includes GeneCards®, the leading human gene
database; LifeMap Discovery™, the database of embryonic
development, stem cell research and regenerative medicine; and MalaCards,
the human disease database. LifeMap Sciences also markets PanDaTox,
an innovative, recently developed, searchable database that can aid in
the discovery of new antibiotics and biotechnologically beneficial
products.
In addition to database offerings, LifeMap Sciences is BioTime’s
principal marketing subsidiary for research products, including PureStem™
human progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan™
growth media for progenitor cell lines, and cell differentiation media
for non-therapeutic uses, via its LifeMap BioReagents™ portal.
LifeMap Sciences utilizes its databases as part of its online marketing
strategy to reach life sciences researchers at biotech and
pharmaceutical companies and at academic institutions and research
hospitals worldwide.
In a therapeutic discovery collaboration with BioTime, LifeMap’s
scientists utilize LifeMap’s proprietary platform, including LifeMap
Discovery™, its stem cell database along with the GeneCards®
and MalaCards integrated database suite, to aid in the
development of BioTime’s proprietary PureStem™ human progenitor
cell lines into products for the treatment of human diseases, especially
degenerative diseases that might be treatable with cell replacement
therapies. The LifeMap Discovery™ platform will be used to select
the progenitor cell lines that are most likely to be useful in
developing cell-based regenerative medicine therapies for a wide range
of diseases.
About ProSpec-Tany TechnoGene Ltd.
ProSpec (Protein-Specialists) is a leading biotechnology company having
over 19 years of experience specializing in production of
bacterial-derived recombinant proteins. ProSpec produces a wide array of
Cytokines, Growth Factors, Chemokines, Hormones, Enzymes, Viral Antigens
and many other recombinant proteins.
ProSpec’s proprietary protein purification technologies with over a
decade of extensive experience result in low production costs, high
yield, production efficiency, utmost pure products and uncompromising
biological activity at competitive prices. ProSpec provides custom
in-house production services of recombinant proteins tailored to the
customer's needs.
ProSpec provides proteins, services and technology license to a broad
range of customers around the globe from academic and government
research institutions, biotechnology and pharmaceutical companies, as
well as hospitals and reference laboratories.
ProSpec's goal is to supply proteins which are crucial to the research
industry to meet and exceed quality, consistency and requirements by our
customers worldwide. The company welcomes partnerships with
pharmaceutical and industrial companies for development of future
proteins.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a biotechnology
company focused on regenerative medicine and blood plasma volume
expanders. Its broad platform of stem cell technologies is enhanced
through subsidiaries focused on specific fields of application. BioTime
develops and markets research products in the fields of stem cells and
regenerative medicine, including a wide array of proprietary PureStem™
cell lines, HyStem® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly
known as HyStem®-Rx), a biocompatible,
implantable hyaluronan and collagen-based matrix for cell delivery in
human clinical applications. BioTime's therapeutic product development
strategy is pursued through subsidiaries that focus on specific organ
systems and related diseases for which there is a high unmet medical
need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the
treatment of retinal and neural degenerative diseases. BioTime's
subsidiary OrthoCyte Corporation is developing therapeutic applications
of stem cells to treat orthopedic diseases and injuries. Another
subsidiary, OncoCyte Corporation, focuses on the diagnostic and
therapeutic applications of stem cell technology in cancer, including
the diagnostic product PanC-Dx™ currently being developed for the
detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent
stem cell technology to reverse the developmental aging of human cells
to treat cardiovascular and blood cell diseases. BioTime's subsidiary
LifeMap Sciences, Inc. markets GeneCards®, the leading
human gene database, as part of an integrated database suite that also
includes the LifeMap Discovery™ database of embryonic
development, stem cell research and regenerative medicine, and MalaCards,
the human disease database. LifeMap Sciences also markets BioTime
research products and PanDaTox, an innovative, recently
developed, searchable database that can aid in the discovery of new
antibiotics and biotechnologically beneficial products. Asterias
Biotherapeutics, Inc. is a new subsidiary being used to acquire the stem
cell assets of Geron Corporation, including patents and other
intellectual property, biological materials, reagents and equipment for
the development of new therapeutic products for regenerative medicine.
BioTime's lead product, Hextend®, is a blood plasma
volume expander manufactured and distributed in the U.S. by Hospira,
Inc. and in South Korea by CJ CheilJedang Corporation under exclusive
licensing agreements. Additional information about BioTime can be found
on the web at www.biotimeinc.com.
Forward-Looking Statements
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will," "believes,"
"plans," "anticipates," "expects," "estimates") should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime'sSecurities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts
Source: BioTime, Inc.
BioTime, Inc.
Peter Garcia
Chief Financial Officer
510-521-3390,
ext 367
pgarcia@biotimemail.com
or
Judith
Segall
510-521-3390, ext 301
jsegall@biotimemail.com
or
LifeMap
Sciences, Inc.
Kenneth Elsner
COO
781-826-7719
ke@lifemapsc.com